# Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Study · id `cardio:ct-nct01101035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01101035](<https://clinicaltrials.gov/study/NCT01101035>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01101035

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6198 participants.

## Technical summary

Registry record NCT01101035. Randomized; quadruple masking; primary purpose treatment. Start 2010-04-23 (actual); primary completion 2017-05-15 (actual). Results posted on 2018-06-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 6198 participants (enrolled count; ClinicalTrials.gov record NCT01101035, source copy `cardio:ctgov-nct01101035-2018-06-14`, retrieved 2026-10-26)
- Started: 2010-04-23 (actual) (ClinicalTrials.gov record NCT01101035, source copy `cardio:ctgov-nct01101035-2018-06-14`, retrieved 2026-10-26)
- Primary completion: 2017-05-15 (actual) (ClinicalTrials.gov record NCT01101035, source copy `cardio:ctgov-nct01101035-2018-06-14`, retrieved 2026-10-26)
- Completion: 2017-07-18 (actual) (ClinicalTrials.gov record NCT01101035, source copy `cardio:ctgov-nct01101035-2018-06-14`, retrieved 2026-10-26)
- Results first posted: 2018-06-14 (ClinicalTrials.gov record NCT01101035, source copy `cardio:ctgov-nct01101035-2018-06-14`, retrieved 2026-10-26)
- Countries: United States; Mexico (ClinicalTrials.gov record NCT01101035, source copy `cardio:ctgov-nct01101035-2018-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01101035-2018-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
- Acronym: CARES
- Condition: Cardiovascular Disease
- Intervention (Drug): Febuxostat
- Intervention (Drug): Allopurinol
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (`cardio:pubmed-22795277`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (`cardio:pubmed-29527974`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial (`cardio:pubmed-35536764`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: aea5c25aa80c1db2fd8fdefba36d5e3d48fa69758cd812fab8f966c3da0ae7e8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
